Indiana University

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Indiana University sits in the top decile of US sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count).

890 total trials 156 currently recruiting 561 completed top decile by trial count

Indiana University: 890 sponsored US clinical trials, 156 recruiting.

Indiana University sponsors 890 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 561 completed. 104 of these trials are in Phase 3-4 (later-stage) and 126 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease, with 11 trials.

Top-decile sponsor footprint

Indiana University ranks in the top decile of sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 43/100

561 of 688 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

890 total, page 13 of 18

COMPLETED NA

Comparative Effectiveness of Primary Care-based Interventions for Pediatric ADHD

NCT02105142

TERMINATED NA

Comparison of Subcutaneous INFIX and EXFIX for Anterior Pelvic Ring Fractures Requiring Stabilization

NCT02403154

COMPLETED Phase 2

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

NCT02008773

COMPLETED Phase 2

Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy

NCT02097823

COMPLETED NA

A Trial to Assess Optimal Postoperative Feeding Regiments Following Pyloromyotomy

NCT02415049

COMPLETED

Improving Healthcare Systems for Access to Care by Underserved Patients

NCT02235597

COMPLETED

Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease

NCT02194439

COMPLETED NA

The Impact of Burnout on Patient-Centered Care: A Comparative Effectiveness Trial in Mental Health

NCT02146326

TERMINATED Phase 4

Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions

NCT02028325

COMPLETED NA

Comparison of a Bilateral TAP Block and Preperitoneal Instillation of Local Anesthetic for a Total Extraperitoneal (TEP) Repair

NCT02036983

TERMINATED NA

Comparison of AmblyzTM Glasses and Patching for Amblyopia

NCT01973348

COMPLETED NA

Does Instrument-assisted Mobilization Influence Healthy, Short Achilles Tendons?

NCT07075172

COMPLETED Phase 1

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NCT01962961

COMPLETED NA

Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes

NCT01814787

COMPLETED Phase 4

Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy

NCT02213900

TERMINATED NA

Conventional Direct Laryngoscopy Vs. Video Laryngoscopy With The C-MAC For Pyloromyotomy

NCT02775214

TERMINATED NA

Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)

NCT01925885

COMPLETED Phase 1

A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients

NCT01926899

COMPLETED

Aspiring to Awesome- Patient Preference Privacy Selections in EMR

NCT01862133

COMPLETED Phase 4

Effect of Octreotide on the Colonic Motility in Pediatric Patients

NCT01917773

COMPLETED Phase 2

Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis

NCT01912716

COMPLETED Phase 4

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256

COMPLETED NA

At-home Auditory Training Clinical Trial

NCT01950013

TERMINATED Phase 4

Seizure Prophylaxis in Aneurysm Repair

NCT01974700

COMPLETED

Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium

NCT02172898

COMPLETED Early Phase 1

Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation

NCT01909401

TERMINATED Phase 2

The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

NCT01874756

COMPLETED Phase 4

Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

NCT01821690

COMPLETED

Viral Pathogenesis of Early Cystic Fibrosis Lung Disease

NCT01973192

COMPLETED Phase 2

Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

NCT01929083

COMPLETED

Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant

NCT02079584

COMPLETED NA

Telephone Support Program for Lung Cancer Patients and Their Family Caregivers

NCT01993550

COMPLETED NA

Computer-Supported Management of Medical-Legal Issues Impacting Child Health

NCT01800669

TERMINATED Phase 2

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

NCT01808534

TERMINATED

Escalating Temporary Gastric Electrical Stimulation (GES) for Severe Gastroparesis

NCT02164591

COMPLETED Phase 2

Fingolimod in Schizophrenia Patients

NCT01779700

COMPLETED NA

Encourage Healthy Families

NCT01823367

COMPLETED

Dermabond Treatment for Gastric Variceal Bleeding

NCT02037659

COMPLETED

The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome

NCT02112513

COMPLETED NA

Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool

NCT01803009

COMPLETED NA

Evaluating Hearing Aid Service Delivery Models

NCT01788423

COMPLETED NA

Indiana University Dementia Screening Trial

NCT01699503

COMPLETED Phase 3

Sphenopalatine Nerve Block for Headache Tx360

NCT01939314

COMPLETED NA

EUS Ductal Evaluation in One Endoscopic Session for the Diagnosis of Exocrine Pancreas Disease

NCT01997476

COMPLETED NA

Delivering Geospatial Intelligence to Health Care Providers

NCT01567228

COMPLETED

Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures

NCT02037607

COMPLETED NA

Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker Response

NCT01919853

COMPLETED Phase 4

A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD

NCT01750294

COMPLETED Phase 4

Single-shot TAP Block vs Continuous TAP Block

NCT02475031

COMPLETED Phase 1

Meaningful Activity Intervention for Persons With Mild Cognitive Impairment

NCT01843283

← Previous Page 13 of 18 Next →

Phase Distribution

PhaseTrial count
Phase 1 56
Phase 2 70
Phase 3 28
Phase 4 76

What is open in the Indiana University pipeline

156 recruiting of 890 indexed (18% open); 561 completed (63%).

Phase mix: 104 late (III/IV) vs 126 early (I/II) (balanced across stages).

Top condition: Alzheimer Disease (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Indiana University: open-pipeline peers nationwide

Peers matched on 890 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Indiana UniversityUniversity of California, Los AngelesHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterEdwards LifesciencesUniversity of South FloridaVA Office of Research and DevelopmentConvaTec
Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 890 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Indiana University page

890 registered trials is a research-attention snapshot, not an endorsement of Indiana University or any single study.

  • 156 of Indiana University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Alzheimer Disease is the condition Indiana University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Indiana University pipeline card: 890 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.